Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials

Luit Penninga, Christian H. Møller, Finn Gustafsson, Daniel A. Steinbrüchel, Christian Gluud

To cite this version:

HAL Id: hal-00627922
https://hal.archives-ouvertes.fr/hal-00627922
Submitted on 30 Sep 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomized trials

<table>
<thead>
<tr>
<th>Journal:</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>European Journal of Clinical Pharmacology</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Manuscript ID:</th>
</tr>
</thead>
<tbody>
<tr>
<td>EJCP-2010-0239.R1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of submission:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review Article</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date Submitted by the Author:</th>
</tr>
</thead>
<tbody>
<tr>
<td>30-Aug-2010</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Complete List of Authors:</th>
</tr>
</thead>
</table>
| Penninga, Luit; Rigshospitalet, Copenhagen University Hospital, 3344, Copenhagen Trial Unit; Rigshospitalet, CTX, Surgery and Transplantation  
Møller, Christian; Rigshospitalet, Copenhagen University Hospital, Cardiothoracic Surgery, RT 2152  
Gustafsson, Finn; Rigshospitalet, Copenhagen University Hospital, Cardiology, B2142  
Steinbrüchel, Daniel; Rigshospitalet, Copenhagen University Hospital, Cardiothoracic Surgery, RT 2152  
Glud, Christian; Rigshospitalet, Copenhagen University Hospital, 3344, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Cochrane Hepato-biliary Group |
Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation:
Systematic review with meta-analyses and trial sequential analyses of randomized trials

Luit Penninga¹,², Christian H Møller¹,³, Finn Gustafsson⁴, Daniel A Steinbrüchel³, Christian Gluud¹

¹ Copenhagen Trial Unit, Centre for Clinical Intervention Research, Cochrane Hepato-biliary Group, Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
² Department of Surgery and Transplantation C2122, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
³ Department of Cardiothoracic Surgery RT 2152, Rigshospitalet, Copenhagen University Hospital, Dept RT-2152, Copenhagen, Denmark
⁴ Department of Cardiology, B2142, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Corresponding Author: Luit Penninga, MD
E-mail: LP@ctu.rh.dk
Tel +45 3545 7113/ +45 3545 7154
Fax +45 3545 7101
Abstract

Purpose We conducted a systematic review of randomized trials to compare benefits and harms of tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation.

Methods and results We searched electronic databases and bibliographies until April 2010. Our review followed the Cochrane and PRISMA guidelines. The meta-analysis included 10 randomized trials with 952 patients. Tacrolimus was significantly superior to cyclosporine (both formula combined) regarding hypertension (relative risk (RR) 0.8; 95% confidence interval (CI) 0.69-0.93, p=0.003), hyperlipidaemia (RR 0.57; 95% CI 0.44-0.74, p<0.0001), hirsutism (RR 0.17 95% CI 0.04-0.62, p=0.008), and gingival hyperplasia (RR 0.07 95% CI 0.01-0.37, p=0.002). No significant differences between the two calcineurin inhibitors were found regarding acute rejections causing hemodynamic instability, diabetes, renal dysfunction, infection, malignancy, or neurotoxicity.

Tacrolimus was significantly superior to microemulsion cyclosporine regarding mortality (RR 0.64; 95% CI 0.42-0.96, p=0.03), acute severe biopsy-proven rejection (RR 0.71; 95% CI 0.56-0.90, p=0.004), hyperlipidaemia (RR 0.57; 95% CI 0.41-0.79, p=0.0009), hirsutism (RR 0.17 95% CI 0.04-0.62, p=0.008), and gingival hyperplasia (RR 0.07 95% CI 0.01-0.37, p=0.002). Tacrolimus was significantly superior to oil-based cyclosporine regarding hypertension (RR 0.66; 95% CI 0.54-0.80, p<0.0001) and hyperlipidaemia (RR 0.57; 95% CI 0.38-0.87, p=0.009).

Conclusion Tacrolimus seems to be superior to cyclosporine in heart transplanted patients regarding hypertension, hyperlipidaemia, gingival hyperplasia and hirsutism. In addition, tacrolimus seems to be superior to microemulsion cyclosporine in heart transplanted patients regarding a number of outcomes including death. More trials with low risk of bias are needed to determine if the results of the present meta-analysis can be confirmed.
Keywords Heart transplantation · Cyclosporine · Tacrolimus · Calcineurin inhibitors · Meta-analysis
**Introduction**

The therapeutic success of heart transplantation has been largely attributable to the development of effective and balanced immunosuppressive treatment regimens [1,2]. Especially the calcineurin inhibitors were essential in reducing acute rejection and improving early survival [2]. Two calcineurin inhibitors, cyclosporine and tacrolimus, are currently used as primary immunosuppression in heart transplant recipients [1,2].

Cyclosporine was discovered in 1971, and in 1983 the drug was approved for prevention or treatment of transplant rejection [3]. To overcome the intra-individual and inter-individual differences in absorption and bioavailability of the original oil-based formulation of cyclosporine (Sandimmune®), a micro-emulsion formula of cyclosporine (Neoral®) was introduced in the 1990s [3].

Tacrolimus (Prograf®) was discovered in the early 1980s and from 1989 used for the prevention of liver transplant rejection [3,4]. Since then, its use expanded rapidly into transplantation of other organs [3]. Both cyclosporine and tacrolimus inhibit the action of the phosphatase calcineurin. Calcineurin regulates the transport of NFAT (nuclear factor of activated T-cells, which is a transcription factor regulating lymphokine gene transcription. Cyclosporine and tacrolimus exert their cellular effects on the action of calcineurin through different cytoplasmatic receptors, as cyclosporine binds to cyclophilins and tacrolimus binds to FK-binding proteins [5]. Differences in adverse effects, safety and tolerability between cyclosporine and tacrolimus have been observed, but the toxicodynamic molecular mechanism of both drugs are still largely unknown and the involvement of calcineurin inhibition in calcineurin inhibitor toxicity is unclear [6].
To date several randomized trials have compared tacrolimus vs. cyclosporine, but results have been inconsistent and optimal immunosuppressive maintenance therapy continues to be debated [5,6].

We conducted this systematic review to compare benefits and harms of tacrolimus vs. cyclosporine in heart transplant recipients.

**Methods**

**Trial selection and characteristics**

Our review followed the Cochrane Collaboration [7] and PRISMA guidelines [8]. A protocol was developed (www.ctu.dk/protocols) and we included all randomized trials comparing tacrolimus versus cyclosporine after first-time isolated heart-transplantation. We required that all included patients received the same additional immunosuppressive therapy within each trial. Our preselected outcome measures were mortality, acute severe rejection defined as cardiac biopsies of grade 3A or higher according to the classification of the ISHLT (equivalent to grade H2R in the recently revised classification) [9]; acute rejection causing haemodynamic instability; Cytomegalovirus (CMV) infection; basocellular skin cancer; all malignancies excluding basocellular skin cancer; arterial hypertension; diabetes mellitus; hyperlipidaemia; total serum cholesterol; renal failure requiring haemodialysis; serum creatinine levels; neurotoxicity; hirsutism; and gingival hyperplasia. Our preselected subgroup analyses included 1) low-risk bias compared to high-risk bias trials 2) micro-emulsion cyclosporine compared to oil-based cyclosporine formulation 3) total population (adult and paediatric studies) compared to adult studies only (www.ctu.dk/protocols).

**Search strategy**

We searched The Cochrane Central Register of Controlled Clinical Trials (CENTRAL), MEDLINE, EMBASE, and the Science Citation Index Expanded (to April 2010) [10]. Search terms...
were (c*closporin* or CyA or Neoral* or Sandimmun*) combined with (tacrolimus or FK506 or FK 506 or Prograf) and ‘heart transplantation’ [MESH term] and (random* or blind* or placebo* or meta-analysis).

We scanned bibliographies of relevant articles for additional trials. We had no restrictions to blinding, language, or publication status.

**Data extraction and quality assessment**

Three authors independently assessed trial eligibility (LP, CHM and FG). We assessed the impact of bias risk by evaluating the trials with respect to generation of the allocation sequence, allocation concealment, blinding, and reporting of incomplete outcome data [11]. Generation of the allocation sequence was considered adequate when generated by a computer, random-number table, shuffling of cards, or something similar. Allocation concealment was considered adequate when allocation of patients involved a central independent unit, such as an on-site locked computer, sealed envelopes or something similar. Blinding was adequate if the trial was described as double-blind and the method of blinding involved identical active drugs. Post-randomization exclusion of patients was registered. When possible we converted per-protocol to intention-to-treat-analysis. Bias risk was assessed without blinding by 3 authors [11].

**Quantitative data synthesis**

We used Cochrane Collaboration Software (RevMan 5.0.22). Data were analysed with both fixed-effect and random-effects models. In case of discrepancy regarding significance between the two models both results were reported. Otherwise, only results from the random-effects model were reported. Data were presented as relative risk (RR) with values less than 1.0 favouring tacrolimus,
and with 95% confidence intervals (CI). Heterogeneity was assessed with $I^2$, which describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). $I^2$ lies between 0% (no heterogeneity) and 100% (maximal heterogeneity) [12]. Test of interaction was performed to evaluate the difference between the 2 estimates [13].

**Trial sequential analysis**

Trial sequential analysis was applied as cumulative meta-analyses are at risk of producing random errors because of sparse data or repetitive testing on accumulating data [14]. To minimize random errors we calculated the required information size (i.e., the number of participants needed in a meta-analysis to detect or reject a certain intervention effect) [14]. Information size calculation also accounted for the diversity present in the meta-analysis. In our meta-analysis, information size was based on the assumption of a plausible RR reduction of 20% [14]. The underlying assumption of trial sequential analysis is that significance testing may be performed each time a new trial is added to the meta-analysis. We added the trials according to the year of publication. On the basis of the required information size and risk for type I and type II errors trial sequential monitoring boundaries were constructed [14]. These boundaries will determine the statistical inference one may draw regarding the cumulative meta-analysis that has not reached the required information size. If a trial sequential monitoring boundary is crossed before the required information size is reached in a cumulative meta-analysis, firm evidence may have been established and further trials are superfluous. On the other hand, if the boundaries are not surpassed, it is most probably necessary to continue doing trials in order to detect or reject a certain intervention effect. We used as defaults a type I error of 5%, type II error of 20%, and adjusted the information size for diversity unless otherwise stated [14].
Results

Figure 1 depicts the results of the search strategy. Database searches identified 450 references. Exclusion of duplicates and irrelevant references left 11 randomized trials published in 25 publications [15-39]. One trial could not be included in the meta-analysis as none of the outcome measures were addressed [29]. We confirmed with the authors that all patients only participated once in the trials [28,30].

The meta-analyses involved 10 trials with a total of 952 patients (table 1): 486 patients were randomized to tacrolimus and 466 patients to cyclosporine [15,16,19,20,24-28,30]). Three trials with 192 patients compared tacrolimus with the old formula oil-based cyclosporine [24,26,27] and seven trials with 760 patients compared tacrolimus with the new formula microemulsion cyclosporine [15,16,19,20,25,28,30].

In 8 trials the population consisted of adult patients [15,19,20,24-28,30], while in 1 trial the population consisted of a combination of adult and paediatric patients [16], and in 1 trial only paediatric patients were included [25].

Concomitant immunosuppressive treatment was the same within all trials except for one where the patients were randomized to 3 groups: one receiving cyclosporine and mycophenolate mofetil, one receiving tacrolimus and mycophenolate mofetil, and one receiving tacrolimus and sirolimus [19]. We therefore excluded the latter group of our analyses. Immunosuppressive treatment varied within trials. All patients were treated with steroids. As antiproliferative agent azathioprine (7 trials [15,16,24-28]) or mycophenolate mofetil (3 trials [19,20,30]) was used. Induction therapy was used for all patients in 4 trials [15,25,26,28], for some of the patients in 3 trials [19,24,27], and for none.
in 3 trials [16,20,30]. In case induction therapy was used, either anti-thymocyte globulin (ATG) or 
muramomab-CD3 (OKT3®) was administered [15,25,26,28]. Patients were followed from 6 months 
to 5 years. 

Trial methodology was inadequately reported in the majority of trials (table 2). All trials were 
considered trials with high risk of bias.

**Mortality**

Ten trials reported on mortality, and overall no significant difference in mortality was found 
between tacrolimus and cyclosporine (relative risk (RR) 0.78; 95% CI 0.54-1.13, p = 0.19). 
Tacrolimus was significantly superior to microemulsion cyclosporine (RR 0.64; 95% CI 0.42-0.96, 
p=0.03). No significant difference in mortality between tacrolimus and oil-based cyclosporine was 
found (RR 1.79; 95% CI 0.77-4.15, p=0.17). Test of interaction showed significant difference in 
intervention effect on mortality between the oil-based and microemulsion cyclosporine formulas 
(p=0.04).

The significant difference in mortality between tacrolimus and microemulsion cyclosporine, 
however, disappeared when the studies including paediatric patients were excluded (RR 0.66; 95% 
CI 0.40-1.09, p=0.10). Test of interaction showed no significant differences in mortality between 
the paediatric and adult cyclosporine subgroups (p=0.89). This suggests that the lack of significance 
caused by withdrawing paediatric studies was solely caused by reducing the number of patients in 
the groups.

**Acute rejection**
No significant difference in grade 3A or higher rejection was found between tacrolimus and (both formula combined) cyclosporine (RR 0.86; 95% CI 0.62-1.20, p=0.38). However, tacrolimus was associated with a significant reduction in Grade 3A or higher rejection compared to microemulsion cyclosporine (RR 0.71; 95% CI 0.56-0.90, p=0.004).

Rejection causing haemodynamic instability was reported in 5 trials comparing tacrolimus versus microemulsion cyclosporine and no significant difference was found (RR 0.96; 95% CI 0.34-1.38, p=0.29).

**Infections**

Infections were analysed as number of patients who experienced at least one episode of infection. No significant difference in proportion of patients with infection was found between tacrolimus and cyclosporine (RR 1.01; 95% CI 0.84-1.21, p=0.91). Neither was any significant difference found when subgroup analysis for the microemulsion and oil-based cyclosporine was applied. In addition, 2 trials compared number of patients with CMV infection for tacrolimus versus microemulsion cyclosporine, and no significant difference was found (RR 1.03; 95% CI 0.75-1.42, p=0.85).

**Malignancies**

According to our protocol we analysed malignancies as basocellular skin cancer and all other cancers excluding basocellular skin cancer. Three trials found no significant difference between tacrolimus versus microemulsion cyclosporine on basocellular skin cancer (RR 1.20; 95% CI 0.29-4.93, p=0.80). Four trials reported on other cancers and found no significant difference between tacrolimus and cyclosporine (RR 0.57; 95% CI 0.20-1.63, p=0.85). Nor did we find any significant difference when subgroup analysis for the microemulsion and oil-based cyclosporine was applied.
Hypertension

Eight trials found significantly less hypertension in patients treated with tacrolimus compared with cyclosporine (RR 0.80; 95% CI 0.69-0.93, p=0.003). In addition subgroup analysis showed that hypertension was less common for tacrolimus compared with oil-based cyclosporine (RR 0.66; 95% CI 0.54-0.80, p<0.0001). An insignificant trend was seen towards less hypertension for tacrolimus compared with microemulsion cyclosporine (RR 0.88; 95% CI 0.77-1.01, p=0.07). The difference was significant when a fixed-effect model was applied (RR 0.86; 95% CI 0.78-0.95, p=0.003).

Hyperlipidaemia

Four trials reported on the number of patients treated pharmacologically for hyperlipidaemia and 5 trials reported on total serum cholesterol. Significantly less patients treated with tacrolimus received treatment for hyperlipidaemia compared with cyclosporine (RR 0.57; 95% CI 0.44-0.74, p<0.0001). This was both seen for patients treated with oil-based cyclosporine (RR 0.57; 95% CI 0.38-0.87, p=0.009) and microemulsion cyclosporine (RR 0.57 95% CI 0.41-0.79, p=0.0009).

In addition, we found that tacrolimus significantly lowers total cholesterol compared with cyclosporine (mean difference 0.4 mmol/L; 95% CI -0.66 to -0.22 mmol/L, p<0.0001). This was both seen for the oil-based (p=0.005) as for the microemulsion (p=0.002) subgroups, and the effect was seen even though in some of the trials more patients in the cyclosporine group were on cholesterol lowering therapy.

Diabetes

Eight trials reported on diabetes. An insignificant trend towards more diabetes was seen in tacrolimus compared with cyclosporine (RR 1.35; 95% CI 0.93-1.94, p=0.11). No significant difference was seen for subgroup analyses on oil-based cyclosporine (RR 1.07, 95% CI 0.40-2.90,
p=0.89) and microemulsion cyclosporine (RR 1.50, 95% CI 0.90-2.50, p=0.12). When the fixed-effect model was applied, we found significant differences between tacrolimus and cyclosporine (RR 1.24; 95% CI 1.02-1.49, p=0.03) and tacrolimus and microemulsion cyclosporine (RR 1.25 95% CI 1.03-1.51, p=0.02).

Renal function

No significant difference between tacrolimus and cyclosporine was seen concerning renal failure requiring haemodialysis (RR 1.45; 95% CI 0.50-4.26, p=0.49). In addition no significant difference was seen for subgroup analyses on oil-based cyclosporine and microemulsion cyclosporine.

Serum creatinine at end of the trials (n=6) was 8 µmol/L lower in patients treated with tacrolimus compared with cyclosporine, however, this difference was not significant (95% CI -18.3 to -1.7 µmol/L, p=0.11). Nor was any significant difference seen in serum creatinine for subgroup analyses on oil-based cyclosporine and microemulsion cyclosporine.

Chronic allograft vasculopathy

Five trials reported on chronic allograft vasculopathy, and no significant difference was found for tacrolimus compared with cyclosporine (RR 1.22; 95% CI 0.72-2.05, p=0.46). Nor was any difference found for subgroup analysis on oil-based cyclosporine and microemulsion cyclosporine.

Hirsutism and gingival hyperplasia

Hirsutism was reported in 2 trials and was significantly less frequent seen in patients treated with tacrolimus than microemulsion cyclosporine (RR 0.17; 95% CI 0.04-0.62, p=0.008). Gingival hyperplasia was reported in three trials and was significantly less frequent seen in patients treated with tacrolimus than with microemulsion cyclosporine (RR 0.07; 95% CI 0.01-0.37, p=0.002).
Neurotoxicity

Neurotoxicity was reported in 5 trials and was analysed as number of patients who experienced at least one neurotoxic reaction or stroke. No significant difference was observed (RR 1.31; 95% CI 0.58-3.00, p=0.50). Nor was any significant difference detected when subgroup analysis for the microemulsion and oil-based cyclosporine was applied.

Adult patients

We performed subgroup analysis for only adult patients by excluding the 2 trials including only or partly paediatric patients [16,25]. We did not find any differences for any of the outcome measures except for the difference in mortality, which was described above.

Trial sequential analysis

Trial sequential analysis was performed for the statistical significant differences in mortality seen for both the tacrolimus vs. oil-based cyclosporine group as well for the tacrolimus versus microemulsion cyclosporine group. In none of the analyses was the required information size obtained and none of the trials sequential monitoring boundaries were broken by the cumulative Z-curve.

Discussion

Principal findings

Our systematic review has generated a number of important findings. Tacrolimus seems to be significantly superior to both types of cyclosporine as regards hypertension, hyperlipidaemia,
hirsutism, and gingival hyperplasia. Furthermore tacrolimus seems to be significantly superior to microemulsion cyclosporine regarding mortality and acute severe biopsy proven rejection.

**Strengths**

Our systematic review of randomized trials offers a number of advantages. We conducted our review according to a protocol following the recommendations of the Cochrane Collaboration [7] and published our protocol before the conduct of the review (www.ctu.dk/protocols). We systematically searched a number of databases and reference lists for randomized trials, which should have reduced selection bias to a minimum [40]. We selected trials and extracted data in triplicate. We conducted sensitivity analyses using different models. We considered risk of systematic errors (‘bias’), risks of random errors (‘play of chance’), as well as risk of design errors (e.g., type of cyclosporine) [40]. We reported our findings in accordance with PRISMA [8].

**Limitations**

This systematic review also encompasses some limitations. The quality and quantity of available evidence limit our findings and interpretations. All trials had high risk of bias [40]. Moreover, only few patients with relatively few outcomes were included in the trials. Hence, risks of random errors are potential explanations of our findings as suggested by our trial sequential analyses on mortality. In addition, patients included in randomized trials may not be representative of the general patient population. For instance most trials included in the current review did not include patients who were bridged to transplantation with a left ventricular device. The proportion of patients bridged to transplantation with an assist device has been increasing in the general heart transplantation population and consisted of 19% in a recent analysis [1]. Moreover, in recent years heart transplant recipients have become older during the technical evolution, with currently 25% of all heart
transplants performed in people over 60 years of age [1]. These factors could potentially influence the external validity of the included trials.

**Perspective**

In our meta-analysis tacrolimus was found superior to the new microemulsion cyclosporine concerning mortality in terms of risk of dying, but no significant difference between tacrolimus and the old formula oil-based cyclosporine was observed. The question arises how this difference can be explained, as microemulsion cyclosporine was introduced to overcome the differences in absorption and oral bioavailability of the original oil-based formulation of cyclosporine [2]. Microemulsion cyclosporine results in higher maximum cyclosporine concentrations than oil-based cyclosporine even when cyclosporine trough (C0) levels are similar, which might influence tolerability and toxicity. A randomized multicenter trial comparing both cyclosporine formulas found more consistent bioavailability of the microemulsion formula resulting in less severe acute rejection in patients treated with the new formula, however, no significant difference in mortality was found at 24 months follow-up in 380 patients [41].

Concerning the difference in mortality observed for the two different cyclosporine formulas in our meta-analysis, it should be noted that clinical experience with tacrolimus was more limited in the trials comparing this drug with oil-based cyclosporine compared to the trials comparing tacrolimus with microemulsion cyclosporine, and tacrolimus blood target levels were higher in the trials with oil-based cyclosporine compared to the trials with microemulsion cyclosporine [15-21,21-28,30]. However, a randomized trial comparing low and high tacrolimus doses in heart transplant recipients did not find any significant difference in mortality, but a more favourable safety profile for the patients treated with a low tacrolimus dose [42].
Traditionally cyclosporine dosing has been based on trough cyclosporine level (C0) monitoring [43]. Cyclosporine level at 2 hours post-dose (C2) has though been found to be the best single time-point predictor of 0 to 4-hour abbreviated area under the absorption curve (AUC0-4) in heart, lung, kidney and liver transplant recipients [43,44]. Clinical benefits have been shown for other solid organ recipients when C2 monitoring was applied compared to C0 [44]. For heart transplant recipients the picture is more unclear as one large trial did not find a correlation between C2 levels and the incidence of rejection [44]. It appears though, that in general a lower C2 level may be sufficient to prevent rejection, and with lower levels different adverse effects might be expected [43,44]. None of the trials in this meta-analysis applied C2 levels for therapeutic drug monitoring of cyclosporine, and we were therefore not able to analyze C0 compared to C2 monitoring in our trial.

The statistical significant difference in mortality between tacrolimus and microemulsion cyclosporine disappeared when two trials including paediatric patients were excluded. However results for the different trials were consistent and none of the trials found tacrolimus to be inferior to cyclosporine. No significant difference between adult and paediatric patients was found when test of interaction was performed. This suggests that the lack of significance caused by withdrawing paediatric studies was caused by reducing the number of patients in the groups.

Our meta-analysis found tacrolimus to be associated with less severe acute biopsy proven rejection compared with microemulsion cyclosporine. This is in line with observational data from The ISHLT showing that 19% of patients who at transplant discharge were receiving tacrolimus and mycophenolate mofetil suffered a treated rejection as compared to 27% of patients receiving cyclosporine and mycophenolate mofetil (p<0.0001) [1].
Another meta-analysis regarding tacrolimus versus microemulsion cyclosporine has been published, and results are slightly different from our systematic review [45]. This might be explained by the following: we found additional randomized trials comparing tacrolimus with microemulsion cyclosporine [30], we excluded studies which were not properly randomized [46], and we excluded study groups where there were differences in concomitant immunosuppressive medication between the tacrolimus and cyclosporine treatment groups [19]. Furthermore, we included trials comparing tacrolimus with oil-based cyclosporine [24,26,27].

Traditionally, immunosuppressive treatment for heart transplantation has gained much experience from knowledge regarding other types of organ transplantation. A meta-analysis comparing tacrolimus versus cyclosporine in 3813 liver transplant recipients found tacrolimus to be superior to cyclosporine in improving patient and graft survival and preventing acute rejection after liver transplantation, however, tacrolimus was significantly more diabetogenic than cyclosporine [47]. A meta-analysis comparing tacrolimus versus cyclosporine in 4102 kidney transplant recipients found tacrolimus to be superior to cyclosporine in improving graft survival and preventing acute rejection after kidney transplantation, however, tacrolimus was found to increase post-transplant diabetes, neurological, and gastrointestinal adverse effects [48]. The reduction in acute rejection and mortality seen in kidney and liver transplant recipients treated with tacrolimus was only seen in our subgroup of heart transplant recipients where tacrolimus was compared to microemulsion cyclosporine. In contrast to kidney and liver transplant recipients we did not find a significant difference on diabetes in heart transplant recipients, however, an insignificant trend towards more diabetes in the tacrolimus group was seen.

**Conclusion**
Recognizing the limitations of the study due to the size and nature of the included trials, our systematic review shows that tacrolimus seems superior to cyclosporine in heart transplant recipients regarding hypertension, hyperlipidaemia, hirsutism and gingival hyperplasia. In addition, tacrolimus seems to be superior to microemulsion cyclosporine regarding mortality and acute severe biopsy-proven rejection. Given the result of our analysis it appears that an appropriately sized, randomized trial of tacrolimus versus microemulsion cyclosporine using contemporary target levels and adjunctive immunosuppression in cardiac transplantation is warranted to determine if the results of the present meta-analysis can be confirmed.

Acknowledgements

This work was supported by a grant from the Rigshospitalet Research Council to LP.

Supplementary material

Supplementary material (forrest plots of all meta-analyses and an additional table on immunosuppressive treatment strategies and drug target levels of the included studies) is available at European Journal of Clinical Pharmacology online.
Reference List


Table 1. Characteristics of included trials.

<table>
<thead>
<tr>
<th>Trial</th>
<th>Number of patients</th>
<th>Age (Y)</th>
<th>Follow-up period (mo)</th>
<th>Adult/Paediat</th>
<th>Oil-based/Micro-emulsion</th>
<th>Cyclosporine</th>
</tr>
</thead>
</table>
| Rinak 
  1997                   | 25                 | 49/53     | 12                     | A             | Oil-based                  |              |
| Rechal 
  1998                   | 82                 | 50/52     | 36                     | A             | Oil-based                  |              |
| Taylor 
  1999                   | 85                 | 53/53     | 12                     | A             | Oil-based                  |              |
| Metser 
  2004                   | 60                 | 55/55     | 24                     | A             | Micro emulsion             |              |
| Wang 
  2004                   | 21                 | 49/44     | 6                      | A             | Micro emulsion             |              |
| Pollock-BarZiv 
  2005              | 26                 | 4/5       | 26                     | P             | Micro emulsion             |              |
| Grimm 
  2006                   | 314                | 51/51     | 18                     | A             | Micro emulsion             |              |
| Kobash 
  2006 A               | 67                 | 34/28     | 60                     | A/P           | Micro emulsion             |              |
| Kobash 
  2006 B               | 223                | 54/51     | 12                     | A             | Micro emulsion             |              |
| Wang 
  2008                   | 49                 | Unknown   | 36                     | A             | Micro emulsion             |              |
Table 2 Assessment of methodology quality

<table>
<thead>
<tr>
<th>Trial</th>
<th>Allocation sequence</th>
<th>Allocation concealment</th>
<th>Blinding</th>
<th>Intention to treat</th>
<th>Incomplete outcome data addressed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinaldi 1997</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No – only biopsies</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Reichart 1998</td>
<td>Adequate</td>
<td>Adequate</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Taylor 1999</td>
<td>Unclear</td>
<td>Adequate</td>
<td>No – only biopsies</td>
<td>Unclear</td>
<td>Unclear</td>
</tr>
<tr>
<td>Meiser 2004</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Wang 2004</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Pollock-BarZiv</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No – only biopsies</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grimm 2006</td>
<td>Adequate</td>
<td>Adequate</td>
<td>No – only biopsies</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Kobashigawa 2006</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No – only biopsies</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K obashigawa 2006</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang 2008</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Figure legends

Figure 1. Diagram of identification of randomized trials for inclusion

Figure 2. Intervention effect of tacrolimus vs. cyclosporine on mortality

Figure 3. Intervention effect of tacrolimus vs. cyclosporine on biopsy proven acute rejection ≥3a

Figure 4. Intervention effect of tacrolimus vs. cyclosporine on hypertension

Figure 5. Intervention effect of tacrolimus vs. cyclosporine on hyperlipidaemia requiring treatment

Figure 6. Intervention effect of tacrolimus vs. cyclosporine on post-transplant diabetes

Figure legends to supplementary electronic material

Figure 7. Intervention effect of tacrolimus vs. cyclosporine on rejection causing hemodynamic instability

Figure 8. Intervention effect of tacrolimus vs. cyclosporine on infection rate

Figure 9. Intervention effect of tacrolimus vs. cyclosporine on CMV-infection rate

Figure 10. Intervention effect of tacrolimus vs. cyclosporine on malignancy

Figure 11. Intervention effect of tacrolimus vs. cyclosporine on basocellular skin cancer

Figure 12. Intervention effect of tacrolimus vs. cyclosporine on renalfailure requiring haemodialysis

Figure 13. Intervention effect of tacrolimus vs. cyclosporine on serum creatinine (µmol/L)

Figure 14. Intervention effect of tacrolimus vs. cyclosporine on chronic allograft vasculopathy

Figure 15. Intervention effect of tacrolimus vs. cyclosporine on hirsutism

Figure 16. Intervention effect of tacrolimus vs. cyclosporine on gingival hyperplasia

Figure 17. Intervention effect of tacrolimus vs. cyclosporine on neurotoxicity
Figure 18. Intervention effect of tacrolimus vs. cyclosporine on total blood cholesterol (mmol/L)

<table>
<thead>
<tr>
<th>Trial</th>
<th>Type of cyclosporine</th>
<th>Cyclosporine trough target/dose</th>
<th>Tacrolimus dose (mg/kg/d)/Target (ng/dl)</th>
<th>Azathioprine/MMF dose</th>
<th>Induction therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinaldi 1997</td>
<td>Oil-based</td>
<td>0-1 mo: 180-360 &gt;1 mo: 80-180 (2-6 mg/kg/d)</td>
<td>0-12: 15-25 (0.15 mg/kg/d) Reduced during study</td>
<td>Azathioprine: Pre-operat: 4 mg/kg Maintenance: 1-2 mg/kg</td>
<td>Yes, Rabbit ATG</td>
</tr>
<tr>
<td>Reichart 1998</td>
<td>Oil-based</td>
<td>0-6 mo: 200-400 &gt;6 mo: 150-250</td>
<td>0-28 d: 15-25 (0.3 mg/kg/d); &gt;28 d: 10-20 Later adjusted to 0-12 mo: &lt;15 (&lt;0.3 mg/kg/d)</td>
<td>Azathioprine: 210 +/- 147 Cum. Dosis (Tacrolimus treatment) 304 +/- 125 Cum. Dosis (Ciclosporin treatment)</td>
<td>Partly, ATG</td>
</tr>
<tr>
<td>Taylor 1999</td>
<td>Oil-based</td>
<td>0-1 mo: 250-600 &gt;1-3 mo: 200-400 &gt;3 mo: 150-250</td>
<td>0-1 mo: 10-20 &gt;1-3 mo: 10-15 &gt;3 mo: 5-10</td>
<td>Azathioprine: Pre-operat: 4 mg/kg Maintenance: 2 mg/kg</td>
<td>Partly, ATG in high-risk patients</td>
</tr>
<tr>
<td>Meiser 2004</td>
<td>Micro emulsion</td>
<td>0-6 mo: 200-300 &gt;6 mo: 100-200</td>
<td>0-6 mo: 13-15; &gt;6 mo: 10-12</td>
<td>MMF: 0-6 mo: 2.5-4 ug/ml &gt;3 mo: 5-15</td>
<td>No</td>
</tr>
<tr>
<td>Wang 2004</td>
<td>Micro emulsion</td>
<td>0-3 mo: 300 (6 mg/kg/d)</td>
<td>0-3 mo: 10-15 (0.15 mg/kg/d) &gt;3 mo: 5-15</td>
<td>Azathioprine</td>
<td>Yes, Rabbit ATG</td>
</tr>
<tr>
<td>Pollock-Baziv 2005</td>
<td>Micro emulsion</td>
<td>0-6 mo: 250-325 &gt;6 mo: 200-250</td>
<td>0-6 mo: 10-12 (0.1-0.3 mg/kg/d) &gt;6 mo: 8-10</td>
<td>Azathioprine 2-3 mg/kg/d;</td>
<td>Yes, Polyclonal Rabbit ATG</td>
</tr>
<tr>
<td>Grimm 2006</td>
<td>Micro emulsion</td>
<td>1-3 mo: 200-350 &gt;3 mo: 100-200</td>
<td>1-3 mo: 10-20; &gt;3 mo: 5-15</td>
<td>Azathioprine 2-4 mg/kg/d; WBC&gt;2000 cells/ul</td>
<td>Yes, ATG or OKT3</td>
</tr>
<tr>
<td>Kobashigawa 2006 A</td>
<td>Micro emulsion</td>
<td>0-1 mo: 250-350 &gt;1 mo: 150-250</td>
<td>0-1 mo: 10-15; &gt;1 mo: 5-10</td>
<td>Azathioprine 2 mg/kg/d; WBC&gt;3500 cells/ul</td>
<td>No</td>
</tr>
<tr>
<td>Kobashigawa 2006 B</td>
<td>Micro emulsion</td>
<td>0-3 mo: 200-400 &gt;3 mo: 100-300</td>
<td>0-3 mo: 10-20; &gt;3 mo: 5-15</td>
<td>MMF: Start 3 g/d Target whole blood trough conc 3.5 ng/mL</td>
<td>Partly, ATGAM, OKT3 or RATG allowed, and only encouraged with renal dysfunction</td>
</tr>
<tr>
<td>Wang 2008</td>
<td>Micro emulsion</td>
<td>Unknown</td>
<td>Unknown</td>
<td>MMF</td>
<td>Yes, type unknown</td>
</tr>
</tbody>
</table>

Supplementary material:
Table 3 Immunosuppressive treatment strategies of included trials
Reference List


Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: Systematic review with meta-analyses and trial sequential analyses of randomized trials

Luit Penninga¹,², Christian H Møller¹,³, Finn Gustafsson⁴, Daniel A Steinbrüchel³, Christian Gluud¹

¹ Copenhagen Trial Unit, Centre for Clinical Intervention Research, Cochrane Hepato-biliary Group, Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
² Department of Surgery and Transplantation C2122, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
³ Department of Cardiothoracic Surgery RT 2152, Rigshospitalet, Copenhagen University Hospital, Dept RT-2152, Copenhagen, Denmark
⁴ Department of Cardiology, B2142, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Corresponding Author: Luit Penninga, MD

E-mail: LP@ctu.rh.dk
Tel +45 3545 7113/ +45 3545 7154
Fax +45 3545 7101
Abstract

Purpose We conducted a systematic review of randomized trials to compare benefits and harms of tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation.

Methods and results We searched electronic databases and bibliographies until April 2010. Our review followed the Cochrane and PRISMA guidelines. The meta-analysis included 10 randomized trials with 952 patients. Tacrolimus was significantly superior to cyclosporine (both formula combined) regarding hypertension (relative risk (RR) 0.8; 95% confidence interval (CI) 0.69-0.93, p=0.003), hyperlipidaemia (RR 0.57; 95% CI 0.44-0.74, p<0.0001), hirsutism (RR 0.17 95% CI 0.04-0.62, p=0.008), and gingival hyperplasia (RR 0.07 95% CI 0.01-0.37, p=0.002). No significant differences between the two calcineurin inhibitors were found regarding acute rejections causing hemodynamic instability, diabetes, renal dysfunction, infection, malignancy, or neurotoxicity. Tacrolimus was significantly superior to microemulsion cyclosporine regarding mortality (RR 0.64; 95% CI 0.42-0.96, p=0.03), acute severe biopsy-proven rejection (RR 0.71; 95% CI 0.56-0.90, p=0.004), hyperlipidaemia (RR 0.57; 95% CI 0.41-0.79, p=0.0009), hirsutism (RR 0.17 95% CI 0.04-0.62, p=0.008), and gingival hyperplasia (RR 0.07; 95% CI 0.01-0.37, p=0.002). Tacrolimus was significantly superior to oil-based cyclosporine regarding hypertension (RR 0.66; 95% CI 0.54-0.80, p<0.0001) and hyperlipidaemia (RR 0.57; 95% CI 0.38-0.87, p=0.009).

Conclusion Tacrolimus seems to be superior to cyclosporine in heart transplanted patients regarding hypertension, hyperlipidaemia, gingival hyperplasia and hirsutism. In addition, tacrolimus seems to be superior to microemulsion cyclosporine in heart transplanted patients regarding a number of outcomes including death. More trials with low risk of bias are needed to determine if the results of the present meta-analysis can be confirmed.
Keywords Heart transplantation · Cyclosporine · Tacrolimus · Calcineurin inhibitors · Meta-analysis
**Introduction**

The therapeutic success of heart transplantation has been largely attributable to the development of effective and balanced immunosuppressive treatment regimens [1,2]. Especially the calcineurin inhibitors were essential in reducing acute rejection and improving early survival [2]. Two calcineurin inhibitors, cyclosporine and tacrolimus, are currently used as primary immunosuppression in heart transplant recipients [1,2].

Cyclosporine was discovered in 1971, and in 1983 the drug was approved for prevention or treatment of transplant rejection [3]. To overcome the intra-individual and inter-individual differences in absorption and bioavailability of the original oil-based formulation of cyclosporine (Sandimmune®), a micro-emulsion formula of cyclosporine (Neoral®) was introduced in the 1990s [3].

Tacrolimus (Prograf®) was discovered in the early 1980s and from 1989 used for the prevention of liver transplant rejection [3,4]. Since then, its use expanded rapidly into transplantation of other organs [3]. Both cyclosporine and tacrolimus inhibit the action of the phosphatase calcineurin. Calcineurin regulates the transport of NFAT (nuclear factor of activated T-cells, which is a transcription factor regulating lymphokine gene transcription. Cyclosporine and tacrolimus exert their cellular effects on the action of calcineurin through different cytoplasmatic receptors, as cyclosporine binds to cyclophilins and tacrolimus binds to FK-binding proteins [5]. Differences in adverse effects, safety and tolerability between cyclosporine and tacrolimus have been observed, but the toxicodynamic molecular mechanism of both drugs are still largely unknown and the involvement of calcineurin inhibition in calcineurin inhibitor toxicity is unclear [6].
To date several randomized trials have compared tacrolimus vs. cyclosporine, but results have been inconsistent and optimal immunosuppressive maintenance therapy continues to be debated [5,6]. We conducted this systematic review to compare benefits and harms of tacrolimus vs. cyclosporine in heart transplant recipients.

Methods

Trial selection and characteristics

Our review followed the Cochrane Collaboration [7] and PRISMA guidelines [8]. A protocol was developed (www.ctu.dk/protocols) and we included all randomized trials comparing tacrolimus versus cyclosporine after first-time isolated heart-transplantation. We required that all included patients received the same additional immunosuppressive therapy within each trial. Our preselected outcome measures were mortality, acute severe rejection defined as cardiac biopsies of grade 3A or higher according to the classification of the ISHLT (equivalent to grade H2R in the recently revised classification) [9]; acute rejection causing haemodynamic instability; Cytomegalovirus (CMV) infection; basocellular skin cancer; all malignancies excluding basocellular skin cancer; arterial hypertension; diabetes mellitus; hyperlipidaemia; total serum cholesterol; renal failure requiring haemodialysis; serum creatinine levels; neurotoxicity; hirsutism; and gingival hyperplasia. Our preselected subgroup analyses included 1) low-risk bias compared to high-risk bias trials 2) micro-emulsion cyclosporine compared to oil-based cyclosporine formulation 3) total population (adult and paediatric studies) compared to adult studies only (www.ctu.dk/protocols).

Search strategy

We searched The Cochrane Central Register of Controlled Clinical Trials (CENTRAL), MEDLINE, EMBASE, and the Science Citation Index Expanded (to April 2010) [10]. Search terms
were (c*closporin* or CyA or Neoral* or Sandimmun*) combined with (tacrolimus or FK506 or FK 506 or Prograf) and ‘heart transplantation’ [MESH term] and (random* or blind* or placebo* or meta-analysis).

We scanned bibliographies of relevant articles for additional trials. We had no restrictions to blinding, language, or publication status.

**Data extraction and quality assessment**

Three authors independently assessed trial eligibility (LP, CHM and FG). We assessed the impact of bias risk by evaluating the trials with respect to generation of the allocation sequence, allocation concealment, blinding, and reporting of incomplete outcome data [11]. Generation of the allocation sequence was considered adequate when generated by a computer, random-number table, shuffling of cards, or something similar. Allocation concealment was considered adequate when allocation of patients involved a central independent unit, such as an on-site locked computer, sealed envelopes or something similar. Blinding was adequate if the trial was described as double-blind and the method of blinding involved identical active drugs. Post-randomization exclusion of patients was registered. When possible we converted per-protocol to intention-to-treat-analysis. Bias risk was assessed without blinding by 3 authors [11].

**Quantitative data synthesis**

We used Cochrane Collaboration Software (RevMan 5.0.22). Data were analysed with both fixed-effect and random-effects models. In case of discrepancy regarding significance between the two models both results were reported. Otherwise, only results from the random-effects model were reported. Data were presented as relative risk (RR) with values less than 1.0 favouring tacrolimus,
and with 95% confidence intervals (CI). Heterogeneity was assessed with $I^2$, which describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). $I^2$ lies between 0% (no heterogeneity) and 100% (maximal heterogeneity) [12]. Test of interaction was performed to evaluate the difference between the 2 estimates [13].

**Trial sequential analysis**

Trial sequential analysis was applied as cumulative meta-analyses are at risk of producing random errors because of sparse data or repetitive testing on accumulating data [14]. To minimize random errors we calculated the required information size (i.e., the number of participants needed in a meta-analysis to detect or reject a certain intervention effect) [14]. Information size calculation also accounted for the diversity present in the meta-analysis. In our meta-analysis, information size was based on the assumption of a plausible RR reduction of 20% [14]. The underlying assumption of trial sequential analysis is that significance testing may be performed each time a new trial is added to the meta-analysis. We added the trials according to the year of publication. On the basis of the required information size and risk for type I and type II errors trial sequential monitoring boundaries were constructed [14]. These boundaries will determine the statistical inference one may draw regarding the cumulative meta-analysis that has not reached the required information size. If a trial sequential monitoring boundary is crossed before the required information size is reached in a cumulative meta-analysis, firm evidence may have been established and further trials are superfluous. On the other hand, if the boundaries are not surpassed, it is most probably necessary to continue doing trials in order to detect or reject a certain intervention effect. We used as defaults a type I error of 5%, type II error of 20%, and adjusted the information size for diversity unless otherwise stated [14].
Results

Figure 1 depicts the results of the search strategy. Database searches identified 450 references. Exclusion of duplicates and irrelevant references left 11 randomized trials published in 25 publications [15-39]. One trial could not be included in the meta-analysis as none of the outcome measures were addressed [29]. We confirmed with the authors that all patients only participated once in the trials [28,30].

The meta-analyses involved 10 trials with a total of 952 patients (table 1): 486 patients were randomized to tacrolimus and 466 patients to cyclosporine [15,16,19,20,24-28,30]). Three trials with 192 patients compared tacrolimus with the old formula oil-based cyclosporine [24,26,27] and seven trials with 760 patients compared tacrolimus with the new formula microemulsion cyclosporine [15,16,19,20,25,28,30].

In 8 trials the population consisted of adult patients [15,19,20,24,26-28,30], while in 1 trial the population consisted of a combination of adult and paediatric patients [16], and in 1 trial only paediatric patients were included [25].

Concomitant immunosuppressive treatment was the same within all trials except for one where the patients were randomized to 3 groups: one receiving cyclosporine and mycophenolate mofetil, one receiving tacrolimus and mycophenolate mofetil, and one receiving tacrolimus and sirolimus [19]. We therefore excluded the latter group of our analyses. Immunosuppressive treatment varied within trials. All patients were treated with steroids. As antiproliferative agent azathioprine (7 trials [15,16,24-28]) or mycophenolate mofetil (3 trials [19,20,30]) was used. Induction therapy was used for all patients in 4 trials [15,25,26,28], for some of the patients in 3 trials [19,24,27], and for none
in 3 trials [16,20,30]. In case induction therapy was used, either anti-thymocyte globulin (ATG) or muromonab-CD3 (OKT3®) was administered [15,25,26,28]. Patients were followed from 6 months to 5 years.

Trial methodology was inadequately reported in the majority of trials (table 2). All trials were considered trials with high risk of bias.

**Mortality**

Ten trials reported on mortality, and overall no significant difference in mortality was found between tacrolimus and cyclosporine (relative risk (RR) 0.78; 95% CI 0.54-1.13, p = 0.19).

Tacrolimus was significantly superior to microemulsion cyclosporine (RR 0.64; 95% CI 0.42-0.96, p=0.03). No significant difference in mortality between tacrolimus and oil-based cyclosporine was found (RR 1.79; 95% CI 0.77-4.15, p=0.17). Test of interaction showed significant difference in intervention effect on mortality between the oil-based and microemulsion cyclosporine formulas (p=0.04).

The significant difference in mortality between tacrolimus and microemulsion cyclosporine, however, disappeared when the studies including paediatric patients were excluded (RR 0.66; 95% CI 0.40-1.09, p=0.10). Test of interaction showed no significant differences in mortality between the paediatric and adult cyclosporine subgroups (p=0.89). This suggests that the lack of significance caused by withdrawing paediatric studies was solely caused by reducing the number of patients in the groups.

**Acute rejection**
No significant difference in grade 3A or higher rejection was found between tacrolimus and (both formula combined) cyclosporine (RR 0.86; 95% CI 0.62-1.20, p=0.38). However, tacrolimus was associated with a significant reduction in Grade 3 A or higher rejection compared to microemulsion cyclosporine (RR 0.71; 95% CI 0.56-0.90, p=0.004).

Rejection causing haemodynamic instability was reported in 5 trials comparing tacrolimus versus microemulsion cyclosporine and no significant difference was found (RR 0.96; 95% CI 0.34-1.38, p=0.29).

**Infections**

Infections were analysed as number of patients who experienced at least one episode of infection. No significant difference in proportion of patients with infection was found between tacrolimus and cyclosporine (RR 1.01; 95% CI 0.84-1.21, p=0.91). Neither was any significant difference found when subgroup analysis for the microemulsion and oil-based cyclosporine was applied. In addition 2 trials compared number of patients with CMV infection for tacrolimus versus microemulsion cyclosporine, and no significant difference was found (RR 1.03; 95% CI 0.75-1.42, p=0.85).

**Malignancies**

According to our protocol we analysed malignancies as basocellular skin cancer and all other cancers excluding basocellular skin cancer. Three trials found no significant difference between tacrolimus versus microemulsion cyclosporine on basocellular skin cancer (RR 1.20; 95% CI 0.29-4.93, p=0.80). Four trials reported on other cancers and found no significant difference between tacrolimus and cyclosporine (RR 0.57; 95% CI 0.20-1.63, p=0.85). Nor did we find any significant difference when subgroup analysis for the microemulsion and oil-based cyclosporine was applied.
**Hypertension**

Eight trials found significantly less hypertension in patients treated with tacrolimus compared with cyclosporine (RR 0.80; 95% CI 0.69-0.93, p=0.003). In addition subgroup analysis showed that hypertension was less common for tacrolimus compared with oil-based cyclosporine (RR 0.66; 95% CI 0.54-0.80, p<0.0001). An insignificant trend was seen towards less hypertension for tacrolimus compared with microemulsion cyclosporine (RR 0.88; 95% CI 0.77-1.01, p=0.07). The difference was significant when a fixed-effect model was applied (RR 0.86; 95% CI 0.78-0.95, p=0.003).

**Hyperlipidaemia**

Four trials reported on the number of patients treated pharmacologically for hyperlipidaemia and 5 trials reported on total serum cholesterol. Significantly less patients treated with tacrolimus received treatment for hyperlipidaemia compared with cyclosporine (RR 0.57; 95% CI 0.44-0.74, p<0.0001). This was both seen for patients treated with oil-based cyclosporine (RR 0.57; 95% CI 0.38-0.87, p=0.009) and microemulsion cyclosporine (RR 0.57 95% CI 0.41-0.79, p=0.0009).

In addition, we found that tacrolimus significantly lowers total cholesterol compared with cyclosporine (mean difference 0.4 mmol/L; 95% CI -0.66 to -0.22 mmol/L, p<0.0001). This was both seen for the oil-based (p=0.005) as for the microemulsion (p=0.002) subgroups, and the effect was seen even though in some of the trials more patients in the cyclosporine group were on cholesterol lowering therapy.

**Diabetes**

Eight trials reported on diabetes. An insignificant trend towards more diabetes was seen in tacrolimus compared with cyclosporine (RR 1.35; 95% CI 0.93-1.94, p=0.11). No significant difference was seen for subgroup analyses on oil-based cyclosporine (RR 1.07, 95% CI 0.40-2.90,
p=0.89) and microemulsion cyclosporine (RR 1.50, 95% CI 0.90-2.50, p=0.12). When the fixed-effect model was applied, we found significant differences between tacrolimus and cyclosporine (RR 1.24; 95% CI 1.02-1.49, p=0.03) and tacrolimus and microemulsion cyclosporine (RR 1.25 95% CI 1.03-1.51, p=0.02).

**Renal function**

No significant difference between tacrolimus and cyclosporine was seen concerning renal failure requiring haemodialysis (RR 1.45; 95% CI 0.50-4.26, p=0.49). In addition no significant difference was seen for subgroup analyses on oil-based cyclosporine and microemulsion cyclosporine.

Serum creatinine at end of the trials (n=6) was 8 µmol/L lower in patients treated with tacrolimus compared with cyclosporine, however, this difference was not significant (95% CI -18.3 to -1.7 µmol/L, p=0.11). Nor was any significant difference seen in serum creatinine for subgroup analyses on oil-based cyclosporine and microemulsion cyclosporine.

**Chronic allograft vasculopathy**

Five trials reported on chronic allograft vasculopathy, and no significant difference was found for tacrolimus compared with cyclosporine (RR 1.22; 95% CI 0.72-2.05, p=0.46). Nor was any difference found for subgroup analysis on oil-based cyclosporine and microemulsion cyclosporine.

**Hirsutism and gingival hyperplasia**

Hirsutism was reported in 2 trials and was significantly less frequent seen in patients treated with tacrolimus than microemulsion cyclosporine (RR 0.17; 95% CI 0.04-0.62, p=0.008). Gingival hyperplasia was reported in three trials and was significantly less frequent seen in patients treated with tacrolimus than with microemulsion cyclosporine (RR 0.07; 95% CI 0.01-0.37, p=0.002).
Neurotoxicity

Neurotoxicity was reported in 5 trials and was analysed as number of patients who experienced at least one neurotoxic reaction or stroke. No significant difference was observed (RR 1.31; 95% CI 0.58-3.00, p=0.50). Nor was any significant difference detected when subgroup analysis for the microemulsion and oil-based cyclosporine was applied.

Adult patients

We performed subgroup analysis for only adult patients by excluding the 2 trials including only or partly paediatric patients [16,25]. We did not find any differences for any of the outcome measures except for the difference in mortality, which was described above.

Trial sequential analysis

Trial sequential analysis was performed for the statistical significant differences in mortality seen for both the tacrolimus vs. oil-based cyclosporine group as well for the tacrolimus versus microemulsion cyclosporine group. In none of the analyses was the required information size obtained and none of the trials sequential monitoring boundaries were broken by the cumulative Z-curve.

Discussion

Principal findings

Our systematic review has generated a number of important findings. Tacrolimus seems to be significantly superior to both types of cyclosporine as regards hypertension, hyperlipidaemia,
hirsutism, and gingival hyperplasia. Furthermore tacrolimus seems to be significantly superior to microemulsion cyclosporine regarding mortality and acute severe biopsy proven rejection.

Strengths

Our systematic review of randomized trials offers a number of advantages. We conducted our review according to a protocol following the recommendations of the Cochrane Collaboration [7] and published our protocol before the conduct of the review (www.ctu.dk/protocols). We systematically searched a number of databases and reference lists for randomized trials, which should have reduced selection bias to a minimum [40]. We selected trials and extracted data in triplicate. We conducted sensitivity analyses using different models. We considered risk of systematic errors (‘bias’), risks of random errors (‘play of chance’), as well as risk of design errors (e.g., type of cyclosporine) [40]. We reported our findings in accordance with PRISMA [8].

Limitations

This systematic review also encompasses some limitations. The quality and quantity of available evidence limit our findings and interpretations. All trials had high risk of bias [40]. Moreover, only few patients with relatively few outcomes were included in the trials. Hence, risks of random errors are potential explanations of our findings as suggested by our trial sequential analyses on mortality. In addition, patients included in randomized trials may not be representative of the general patient population. For instance most trials included in the current review did not include patients who were bridged to transplantation with a left ventricular device. The proportion of patients bridged to transplantation with an assist device has been increasing in the general heart transplantation population and consisted of 19% in a recent analysis [1]. Moreover, in recent years heart transplant recipients have become older during the technical evolution, with currently 25% of all heart
transplants performed in people over 60 years of age [1]. These factors could potentially influence
the external validity of the included trials.

**Perspective**

In our meta-analysis tacrolimus was found superior to the new microemulsion cyclosporine
concerning mortality in terms of risk of dying, but no significant difference between tacrolimus and
the old formula oil-based cyclosporine was observed. The question arises how this difference can be
explained, as microemulsion cyclosporine was introduced to overcome the differences in absorption
and oral bioavailability of the original oil-based formulation of cyclosporine [2]. Microemulsion
cyclosporine results in higher maximum cyclosporine concentrations than oil-based cyclosporine
even when cyclosporine trough (C0) levels are similar, which might influence tolerability and
toxicity. A randomized multicenter trial comparing both cyclosporine formulas found more
consistent bioavailability of the microemulsion formula resulting in less severe acute rejection in
patients treated with the new formula, however, no significant difference in mortality was found at
24 months follow-up in 380 patients [41].

Concerning the difference in mortality observed for the two different cyclosporine formulas in our
meta-analysis, it should be noted that clinical experience with tacrolimus was more limited in the
trials comparing this drug with oil-based cyclosporine compared to the trials comparing tacrolimus
with microemulsion cyclosporine, and tacrolimus blood target levels were higher in the trials with
oil-based cyclosporine compared to the trials with microemulsion cyclosporine [15-21,21-28,30].

However, a randomized trial comparing low and high tacrolimus doses in heart transplant recipients
did not find any significant difference in mortality, but a more favourable safety profile for the
patients treated with a low tacrolimus dose [42].
Traditionally cyclosporine dosing has been based on trough cyclosporine level (C0) monitoring [43]. Cyclosporine level at 2 hours post-dose (C2) has though been found to be the best single time-point predictor of 0 to 4-hour abbreviated area under the absorption curve ($\text{AUC}_{0-4}$) in heart, lung, kidney and liver transplant recipients [43,44]. Clinical benefits have been shown for other solid organ recipients when C2 monitoring was applied compared to C0 [44]. For heart transplant recipients the picture is more unclear as one large trial did not find a correlation between C2 levels and the incidence of rejection [44]. It appears though, that in general a lower C2 level may be sufficient to prevent rejection, and with lower levels different adverse effects might be expected [43,44]. None of the trials in this meta-analysis applied C2 levels for therapeutic drug monitoring of cyclosporine, and we were therefore not able to analyze C0 compared to C2 monitoring in our trial.

The statistical significant difference in mortality between tacrolimus and microemulsion cyclosporine disappeared when two trials including paediatric patients were excluded. However results for the different trials were consistent and none of the trials found tacrolimus to be inferior to cyclosporine. No significant difference between adult and paediatric patients was found when test of interaction was performed. This suggests that the lack of significance caused by withdrawing paediatric studies was caused by reducing the number of patients in the groups.

Our meta-analysis found tacrolimus to be associated with less severe acute biopsy proven rejection compared with microemulsion cyclosporine. This is in line with observational data from The ISHLT showing that 19% of patients who at transplant discharge were receiving tacrolimus and mycophenolate mofetil suffered a treated rejection as compared to 27% of patients receiving cyclosporine and mycophenolate mofetil ($p<0.0001$)[1].
Another meta-analysis regarding tacrolimus versus microemulsion cyclosporine has been published, and results are slightly different from our systematic review [45]. This might be explained by the following: we found additional randomized trials comparing tacrolimus with microemulsion cyclosporine [30], we excluded studies which were not properly randomized [46], and we excluded study groups where there were differences in concomitant immunosuppressive medication between the tacrolimus and cyclosporine treatment groups [19]. Furthermore, we included trials comparing tacrolimus with oil-based cyclosporine [24,26,27].

Traditionally, immunosuppressive treatment for heart transplantation has gained much experience from knowledge regarding other types of organ transplantation. A meta-analysis comparing tacrolimus versus cyclosporine in 3813 liver transplant recipients found tacrolimus to be superior to cyclosporine in improving patient and graft survival and preventing acute rejection after liver transplantation, however, tacrolimus was significantly more diabetogenic than cyclosporine [47]. A meta-analysis comparing tacrolimus versus cyclosporine in 4102 kidney transplant recipients found tacrolimus to be superior to cyclosporine in improving graft survival and preventing acute rejection after kidney transplantation, however, tacrolimus was found to increase post-transplant diabetes, neurological, and gastrointestinal adverse effects [48]. The reduction in acute rejection and mortality seen in kidney and liver transplant recipients treated with tacrolimus was only seen in our subgroup of heart transplant recipients where tacrolimus was compared to microemulsion cyclosporine. In contrast to kidney and liver transplant recipients we did not find a significant difference on diabetes in heart transplant recipients, however, an insignificant trend towards more diabetes in the tacrolimus group was seen.

**Conclusion**
Recognizing the limitations of the study due to the size and nature of the included trials, our systematic review shows that tacrolimus seems superior to cyclosporine in heart transplant recipients regarding hypertension, hyperlipidaemia, hirsutism and gingival hyperplasia. In addition, tacrolimus seems to be superior to microemulsion cyclosporine regarding mortality and acute severe biopsy-proven rejection. Given the result of our analysis it appears that an appropriately sized, randomized trial of tacrolimus versus microemulsion cyclosporine using contemporary target levels and adjunctive immunosuppression in cardiac transplantation is warranted to determine if the results of the present meta-analysis can be confirmed.

Acknowledgements

This work was supported by a grant from the Rigshospitalet Research Council to LP.

Supplementary material

Supplementary material (forrest plots of all meta-analyses and an additional table on immunosuppressive treatment strategies and drug target levels of the included studies) is available at European Journal of Clinical Pharmacology online.
Reference List


Table 1. Characteristics of included trials.

<table>
<thead>
<tr>
<th>Trial</th>
<th>Number of patients</th>
<th>Age (Y)</th>
<th>Follow-up period (mo)</th>
<th>Adult/Paediatric</th>
<th>Oil-based/micro-emulsion Cyclosporine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinaldi 1997</td>
<td>25</td>
<td>49/53</td>
<td>12</td>
<td>A</td>
<td>Oil-based</td>
</tr>
<tr>
<td>Reichart 1998</td>
<td>82</td>
<td>50/52</td>
<td>36</td>
<td>A</td>
<td>Oil-based</td>
</tr>
<tr>
<td>Taylor 1999</td>
<td>85</td>
<td>53/53</td>
<td>12</td>
<td>A</td>
<td>Oil-based</td>
</tr>
<tr>
<td>Meiser 2004</td>
<td>60</td>
<td>55/55</td>
<td>24</td>
<td>A</td>
<td>Micro emulsion</td>
</tr>
<tr>
<td>Wang 2004</td>
<td>21</td>
<td>49/44</td>
<td>6</td>
<td>A</td>
<td>Micro emulsion</td>
</tr>
<tr>
<td>Pollock-BarZiv 2005</td>
<td>26</td>
<td>4/5</td>
<td>26</td>
<td>P</td>
<td>Micro emulsion</td>
</tr>
<tr>
<td>Grimm 2006</td>
<td>314</td>
<td>51/51</td>
<td>18</td>
<td>A</td>
<td>Micro emulsion</td>
</tr>
<tr>
<td>Kobashigawa 2006 A</td>
<td>67</td>
<td>34/28</td>
<td>60</td>
<td>A/P</td>
<td>Micro emulsion</td>
</tr>
<tr>
<td>Kobashigawa 2006 B</td>
<td>223</td>
<td>54/51</td>
<td>12</td>
<td>A</td>
<td>Micro emulsion</td>
</tr>
<tr>
<td>Wang 2008</td>
<td>49</td>
<td>Unknown</td>
<td>36</td>
<td>A</td>
<td>Micro emulsion</td>
</tr>
</tbody>
</table>
Table 2 Assessment of methodology quality

<table>
<thead>
<tr>
<th>Trial</th>
<th>Allocation sequence</th>
<th>Allocation concealment</th>
<th>Blinding</th>
<th>Intention to treat</th>
<th>Incomplete outcome data addressed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinaldi 1997</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No – only biopsies</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Reichart 1998</td>
<td>Adequate</td>
<td>Adequate</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Taylor 1999</td>
<td>Unclear</td>
<td>Adequate</td>
<td>No – only biopsies</td>
<td>Unclear</td>
<td>Unclear</td>
</tr>
<tr>
<td>Meiser 2004</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Wang 2004</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No</td>
<td>Yes</td>
<td>Unclear</td>
</tr>
<tr>
<td>Pollock-BarZiv</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No – only biopsies</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grimm 2006</td>
<td>Adequate</td>
<td>Adequate</td>
<td>No – only biopsies</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Kobashigawa</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No – only biopsies</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2006 A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kobashigawa</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2006 B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang 2008</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Figure legends

Figure 1. Diagram of identification of randomized trials for inclusion

Figure 2. Intervention effect of tacrolimus vs. cyclosporine on mortality

Figure 3. Intervention effect of tacrolimus vs. cyclosporine on biopsy proven acute rejection ≥3a

Figure 4. Intervention effect of tacrolimus vs. cyclosporine on hypertension

Figure 5. Intervention effect of tacrolimus vs. cyclosporine on hyperlipidaemia requiring treatment

Figure 6. Intervention effect of tacrolimus vs. cyclosporine on post-transplant diabetes

Figure legends to supplementary electronic material

Figure 7. Intervention effect of tacrolimus vs. cyclosporine on rejection causing hemodynamic instability

Figure 8. Intervention effect of tacrolimus vs. cyclosporine on infection rate

Figure 9. Intervention effect of tacrolimus vs. cyclosporine on CMV-infection rate

Figure 10. Intervention effect of tacrolimus vs. cyclosporine on malignancy

Figure 11. Intervention effect of tacrolimus vs. cyclosporine on basocellular skin cancer

Figure 12. Intervention effect of tacrolimus vs. cyclosporine on renalfailure requiring haemodialysis

Figure 13. Intervention effect of tacrolimus vs. cyclosporine on serum creatinine (µmol/L)

Figure 14. Intervention effect of tacrolimus vs. cyclosporine on chronic allograft vasculopathy

Figure 15. Intervention effect of tacrolimus vs. cyclosporine on hirsutism

Figure 16. Intervention effect of tacrolimus vs. cyclosporine on gingival hyperplasia

Figure 17. Intervention effect of tacrolimus vs. cyclosporine on neurotoxicity
Figure 18. Intervention effect of tacrolimus vs. cyclosporine on total blood cholesterol (mmol/L)

<table>
<thead>
<tr>
<th>Trial</th>
<th>Type of cyclosporine</th>
<th>Cyclosporine trough target/dose</th>
<th>Tacrolimus dose (mg/kg/d)/ Target (mg/dl)</th>
<th>Azathioprine/MMF dose</th>
<th>Induction therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinaldi 1997</td>
<td>Oil-based</td>
<td>0-1 mo: 180-360 &gt;1 mo: 80-180</td>
<td>0-12; 12-25 (0.15 mg/kg/d) Reduced during study</td>
<td>Azathioprine:</td>
<td>Yes, Rabbit ATG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(2-6 mg/kg/d)</td>
<td></td>
<td>Pre-operat: 4 mg/kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maintenance: 1-2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mg/kg</td>
<td></td>
</tr>
<tr>
<td>Reichart 1998</td>
<td>Oil-based</td>
<td>0-6 mo: 200-400 &gt;6 mo: 150-250</td>
<td>0-28 d: 15-25 (0.3 mg/kg/d; &gt;28 d: 10-20 Later adjusted to 0-12 mo: &lt;15 (&lt;0.3 mg/kg/d</td>
<td>Azathioprine:</td>
<td>Partly, ATG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pre-operat: 210 +/- 147 Cum. Dosis (Tacrolimus treatm gr.) 324 +/- 125 Cum. Dosis (Ciclosporin treatm gr.)</td>
<td></td>
</tr>
<tr>
<td>Taylor 1999</td>
<td>Oil-based</td>
<td>0-1 mo: 250-600 1-3 mo: 200-400 &gt;3 mo: 150-250</td>
<td>0-1 mo: 10-20 1-3 mo: 10-15 &gt;3 mo: 5-10</td>
<td>Azathioprine:</td>
<td>Partly, OKT3 in high-risk patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pre-operat: 4 mg/kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maintenance: 2 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Meiser 2004</td>
<td>Micro emulsion</td>
<td>0-6 mo: 200-300 &gt;6 mo: 100-200</td>
<td>0-6 mo: 13-15; &gt;6 mo: 10-12</td>
<td>MMF: 0-6 mo: 2.5-4 ug/ml &gt;3 mo: 5-15</td>
<td>No</td>
</tr>
<tr>
<td>Wang 2004</td>
<td>Micro emulsion</td>
<td>0-3 mo: 300 (6 mg/kg/d)</td>
<td>0-3 mo: 10-20 (0.15 mg/kg/d; &gt;3 mo: 5-15</td>
<td>Azathioprine:</td>
<td>Yes, Rabbit ATG</td>
</tr>
<tr>
<td>Pollock-BarZiv 2005</td>
<td>Micro emulsion</td>
<td>0-6 mo: 250-325 &gt;6 mo: 200-250</td>
<td>0-6 mo: 10-12 (0.1-0.3 mg/kg/d; &gt;6 mo: 8-10</td>
<td>Azathioprine: 2-3 mg/kg/d;</td>
<td>Yes, Polyclonal Rabbit ATG</td>
</tr>
<tr>
<td>Grimm 2006</td>
<td>Micro emulsion</td>
<td>1-3 mo: 200-350 &gt;3 mo: 100-200</td>
<td>1-3 mo: 10-20; &gt;3 mo: 5-15</td>
<td>Azathioprine: 2-4 mg/kg/d; WBC&gt;2000 cells/ul</td>
<td>Yes, ATG or OKT3</td>
</tr>
<tr>
<td>Kobashigawa 2006 A</td>
<td>Micro emulsion</td>
<td>0-1 mo: 250-350; &gt;1 mo: 150-250</td>
<td>0-1 mo: 10-15; &gt;1 mo: 5-10</td>
<td>Azathioprine 2 mg/kg/d; WBC&gt;3500 cells/ul</td>
<td>No</td>
</tr>
<tr>
<td>Kobashigawa 2006 B</td>
<td>Micro emulsion</td>
<td>0-3 mo: 200-400 &gt;3 mo: 100-300</td>
<td>0-3 mo: 10-20; &gt;3 mo: 5-15</td>
<td>MMF: Start 3 g/d Target whole blood trough conc 3-5 mg/mL</td>
<td>Partly, ATGAM, OKT3 or RATG allowed, and only encouraged with renal dysfunction</td>
</tr>
<tr>
<td>Wang 2008</td>
<td>Micro emulsion</td>
<td>Unknown</td>
<td>Unknown</td>
<td>MMF</td>
<td>Yes, type unknown</td>
</tr>
</tbody>
</table>

**Supplementary material:**

Table 3 Immunosuppressive treatment strategies of included trials
Potentially relevant references

- CENTRAL: 76
- Medline: 117
- Embase: 126
- Web of Science: 136
- Other: 8

Duplicates: 199 references

264 references

Irrelevant: 242 references

25 references

11 trials
### Intervention effect of tacrolimus vs. cyclosporine on mortality

64x39mm (300 x 300 DPI)
Intervention effect of tacrolimus vs. cyclosporine on biopsy proven acute rejection ≥3a
64x32mm (300 x 300 DPI)
### Intervention effect of tacrolimus vs. cyclosporine on hypertension

64x36mm (300 x 300 DPI)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Tacrolimus</th>
<th>Cyclosporine</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>M H, Random, 95% CI</td>
<td>M H, Random, 95% CI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ommen 2006</td>
<td>72</td>
<td>137</td>
<td>83</td>
<td>124</td>
</tr>
<tr>
<td>Kobrahtyazade 2008 A</td>
<td>11</td>
<td>33</td>
<td>20</td>
<td>34</td>
</tr>
<tr>
<td>Kobrahtyazade 2008 B</td>
<td>85</td>
<td>103</td>
<td>93</td>
<td>114</td>
</tr>
<tr>
<td>Meiser 2014</td>
<td>28</td>
<td>53</td>
<td>30</td>
<td>36</td>
</tr>
<tr>
<td>Pollack-Baz 2005</td>
<td>6</td>
<td>12</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>320</td>
<td>503</td>
<td>309</td>
<td>70.0%</td>
</tr>
</tbody>
</table>

Total events: 220

Heterogeneity: Tau² = 9.61; Chisq = 9.10; df = 4 (P = 0.04); I² = 51%
Test for overall effect Z = 1.81 (P = 0.07)

1.4.2 Dihydropyridine

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Tacrolimus</th>
<th>Cyclosporine</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>M H, Random, 95% CI</td>
<td>M H, Random, 95% CI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reichard 1998</td>
<td>32</td>
<td>54</td>
<td>25</td>
<td>28</td>
</tr>
<tr>
<td>Rinaldi 1997</td>
<td>9</td>
<td>13</td>
<td>10</td>
<td>16</td>
</tr>
<tr>
<td>Topfer 1999</td>
<td>13</td>
<td>39</td>
<td>24</td>
<td>48</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>186</td>
<td>306</td>
<td>97</td>
<td>202</td>
</tr>
</tbody>
</table>

Total events: 59

Heterogeneity: Tau² = 9.03; Chisq = 9.03; df = 2 (P = 0.06); I² = 0%
Test for overall effect Z = 4.08 (P = 0.0001)

1.4.3 Other calcium channel blockers

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Tacrolimus</th>
<th>Cyclosporine</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>M H, Random, 95% CI</td>
<td>M H, Random, 95% CI</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>429</td>
<td>506</td>
<td>100.0%</td>
<td>0.80 (0.69, 0.93)</td>
</tr>
</tbody>
</table>

Total events: 295

Heterogeneity: Tau² = 9.62; Chisq = 10.27; df = 7 (P = 0.09); I² = 62%
Test for overall effect Z = 2.97 (P = 0.003)
### Intervention effect of tacrolimus vs. cyclosporine on hyperlipidaemia requiring treatment

63x31mm (300 x 300 DPI)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Tacrolimus</th>
<th>Cyclosporine</th>
<th>Weight</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td></td>
<td>M-H, Random, 95% CI</td>
<td>M-H, Random, 95% CI</td>
</tr>
<tr>
<td>Grimm 2004</td>
<td>34</td>
<td>137</td>
<td>52.0%</td>
<td>0.49 [0.41, 0.65]</td>
<td></td>
</tr>
<tr>
<td>Pollock-BarZiv 2006</td>
<td>2</td>
<td>12</td>
<td>7</td>
<td>0.68 [0.60, 0.77]</td>
<td></td>
</tr>
<tr>
<td>Reichart 1999</td>
<td>5</td>
<td>42</td>
<td>7</td>
<td>0.41 [0.19, 0.91]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>45</td>
<td>181</td>
<td>65.4%</td>
<td>0.57 [0.41, 0.75]</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>41</td>
<td>81</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau^2 = 3.00; Chi^2 = 0.45; df = 2 (P = 0.80); I^2 = 0%
Test for overall effect: Z = 3.33 (P = 0.0009)

<table>
<thead>
<tr>
<th>Subtotal 95% CI</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tacrolimus</td>
<td>30.8%</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>30.0%</td>
</tr>
<tr>
<td>Test for overall effect: Z = 2.62 (P = 0.008)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tacrolimus</th>
<th>Cyclosporine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total (95% CI)</td>
<td>230</td>
</tr>
<tr>
<td>100.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td>Risk Ratio</td>
<td>0.57 [0.44, 0.74]</td>
</tr>
<tr>
<td>Risk Ratio</td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 4.24 (P = 0.0001)</td>
<td></td>
</tr>
</tbody>
</table>
Intervention effect of tacrolimus vs. cyclosporine on post-transplant diabetes

64x36mm (300 x 300 DPI)
Intervention effect of tacrolimus vs. cyclosporine on rejection causing hemodynamic instability

64x32mm (300 x 300 DPI)
### Intervention effect of tacrolimus vs. cyclosporine on infection rate

64x29mm (300 x 300 DPI)
### Intervention effect of tacrolimus vs. cyclosporine on CMV-infection rate

64x20mm (300 x 300 DPI)
## Intervention effect of tacrolimus vs. cyclosporine on malignancy

64x31mm (300 x 300 DPI)
Intervention effect of tacrolimus vs. cyclosporine on basocellular skin cancer

64x21mm (300 x 300 DPI)
### Intervention effect of tacrolimus vs. cyclosporine on renal failure requiring haemodialysis

64x31mm (300 x 300 DPI)
### Intervention effect of tacrolimus vs. cyclosporine on serum creatinine (µmol/L)

**69x29mm (300 x 300 DPI)**

#### Table of Intervention Effect

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Tacrolimus Mean (SD)</th>
<th>Cyclosporine Mean (SD)</th>
<th>Mean Difference Mean (SD)</th>
<th>Weight</th>
<th>N, Random, 95% CI</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>122.1 Micromenschen</td>
<td>124.4 (6.9)</td>
<td>126.9 (6.2)</td>
<td>-2.5 (1.4)</td>
<td>0.016</td>
<td>2004</td>
<td></td>
</tr>
<tr>
<td>140.9 Veen</td>
<td>126.4 (8.6)</td>
<td>126.4 (8.7)</td>
<td>0.1 (0.8)</td>
<td>0.001</td>
<td>2005</td>
<td></td>
</tr>
<tr>
<td>219.9 Kovaljov 2005</td>
<td>108.8 (4.2)</td>
<td>122.8 (6.4)</td>
<td>-14.0 (1.4)</td>
<td>0.001</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>220</td>
<td>221</td>
<td>50.0%</td>
<td>-11.7 [-38.6, 7.0]</td>
<td>2006</td>
<td></td>
</tr>
</tbody>
</table>

#### Test for overall effect: Z = 1.22 (P = 0.22)

#### 122.2 6/s-based cyclosporine

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Tacrolimus Mean (SD)</th>
<th>Cyclosporine Mean (SD)</th>
<th>Mean Difference Mean (SD)</th>
<th>Weight</th>
<th>N, Random, 95% CI</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>118.9 Radle 1997</td>
<td>116.7 (7.3)</td>
<td>124.2 (6.0)</td>
<td>-7.5 (1.4)</td>
<td>0.001</td>
<td>1997</td>
<td></td>
</tr>
<tr>
<td>139.9 Rechard 1998</td>
<td>141.4 (17.7)</td>
<td>137.9 (5.4)</td>
<td>3.5 (0.3)</td>
<td>0.001</td>
<td>1999</td>
<td></td>
</tr>
<tr>
<td>105.9 Taylor 1999</td>
<td>110.4 (35.4)</td>
<td>116.3 (30.4)</td>
<td>-5.9 (0.3)</td>
<td>0.001</td>
<td>1999</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>328</td>
<td>305</td>
<td>100.0%</td>
<td>-8.2 [-18.2, 1.7]</td>
<td>1999</td>
<td></td>
</tr>
</tbody>
</table>

#### Test for overall effect: Z = 3.02 (P = 0.01)

#### Test for subgroup differences: Ch² = 5.3, df = 2 (P = 0.07), I² = 40%

---

**Intervention effect of tacrolimus vs. cyclosporine on serum creatinine (µmol/L)**

**69x29mm (300 x 300 DPI)**
### Intervention effect of tacrolimus vs. cyclosporine on chronic allograft vasculopathy

64x31mm (300 x 300 DPI)
### Intervention effect of tacrolimus vs. cyclosporine on hirsutism

64x20mm (300 x 300 DPI)
### Intervention effect of tacrolimus vs. cyclosporine on gingival hyperplasia

64x21mm (300 x 300 DPI)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Tacrolimus</th>
<th>Cyclosporine</th>
<th>Risk Ratio M.H., Random, 95% CI</th>
<th>Risk Ratio M.H., Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
<td></td>
</tr>
<tr>
<td>Oemmen 2006</td>
<td>0</td>
<td>157</td>
<td>0</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>107</td>
<td>33.3%</td>
<td>0.90 [0.80, 1.01]</td>
</tr>
<tr>
<td>Kooshlagha 2006 &amp;</td>
<td>0</td>
<td>103</td>
<td>7</td>
<td>115</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>113</td>
<td>33.3%</td>
<td>0.97 [0.80, 1.23]</td>
</tr>
<tr>
<td>Meiser 2004</td>
<td>0</td>
<td>33</td>
<td>4</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>295</td>
<td>302</td>
<td>100.0%</td>
<td>0.11 [0.01, 1.09]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>295</td>
<td>302</td>
<td>100.0%</td>
<td>0.07 [0.01, 0.41]</td>
</tr>
<tr>
<td>Total events</td>
<td>0</td>
<td>21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity:</td>
<td>Tau^2 = 0.03, Ch^2 = 0.17, df = 2 (P = 0.82), P = 6%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall</td>
<td></td>
<td></td>
<td>Z = 3.13 (P = 0.002)</td>
<td></td>
</tr>
<tr>
<td>effect</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Events</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>295</td>
<td>302</td>
<td>100.0%</td>
<td>0.07 [0.01, 0.41]</td>
</tr>
<tr>
<td>Heterogeneity:</td>
<td>Tau^2 = 0.03, Ch^2 = 0.17, df = 2 (P = 0.82), P = 6%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall</td>
<td></td>
<td></td>
<td>Z = 3.13 (P = 0.002)</td>
<td></td>
</tr>
<tr>
<td>effect</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Intervention effect of tacrolimus vs. cyclosporine on neurotoxicity
64x32mm (300 x 300 DPI)
Intervention effect of tacrolimus vs. cyclosporine on total blood cholesterol (mmol/L)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Tacrolimus</th>
<th>Cyclosporine</th>
<th>Mean Difference</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
<td></td>
</tr>
<tr>
<td>McInnes 2004</td>
<td>4.37</td>
<td>0.98</td>
<td>30</td>
<td>4.81 0.96 30 19.5% 0.44 [0.93, 6.89] 2004</td>
</tr>
<tr>
<td>Kobashigawa 2006 A</td>
<td>4.19</td>
<td>0.72</td>
<td>33</td>
<td>4.5 0.00 34 31.9% 0.34 [0.72, 0.64] 2006</td>
</tr>
<tr>
<td>Okman 2006</td>
<td>4.09</td>
<td>3.3</td>
<td>157</td>
<td>0.3 2.96 157 16.3% 0.41 [0.90, 0.13] 2006</td>
</tr>
<tr>
<td>Kobashigawa 2008 B</td>
<td>4.4</td>
<td>2.48</td>
<td>108</td>
<td>4.73 2.46 115 11.2% 0.33 [0.98, 0.32] 2008</td>
</tr>
<tr>
<td>Subtotal (65% CI)</td>
<td>328</td>
<td>336</td>
<td>764</td>
<td>-0.36 [1.63, 0.63]</td>
</tr>
</tbody>
</table>

Heterogeneity: Test * = 0.03; Chi² = 6.13; df = 5 (P = 0.30); I² = 0%
Test for overall effect: Z = 3.02 (P = 0.002)

1.24 2.O4-based cyclosporine

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Tacrolimus</th>
<th>Cyclosporine</th>
<th>Mean Difference</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
<td></td>
</tr>
<tr>
<td>Taylor 1999</td>
<td>4.91</td>
<td>1.03</td>
<td>39</td>
<td>5.4 1.19 46 21.1% -0.87 [1.14, -0.20] 1999</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>39</td>
<td>46</td>
<td>21.1%</td>
<td>-0.87 [1.14, -0.20]</td>
</tr>
</tbody>
</table>

Heterogeneity: Not applicable
Test for overall effect: Z = 2.70 (P = 0.006)

Total (95% CI)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Tacrolimus</th>
<th>Cyclosporine</th>
<th>Mean Difference</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
<td></td>
</tr>
<tr>
<td></td>
<td>387</td>
<td>382</td>
<td>769</td>
<td>0.44 [0.86, 0.22]</td>
</tr>
</tbody>
</table>

Heterogeneity: Test * = 0.03; Chi² = 1.28; df = 4 (P = 0.99); I² = 0%
Test for overall effect: Z = 3.29 (P = 0.0001)
Test for subgroups difference: Chi² = 1.15; df = 1 (P = 0.29); I² = 13.9%

Favours experimental: Favours control